吉西他滨联合放疗治疗儿童新诊断弥漫性内生性桥脑胶质瘤的I/II期研究
这项I/II期开放标签单臂试验在9例新诊断弥漫性内生性桥脑胶质瘤(DIPG)儿童中评估吉西他滨联合同步超分割放疗的安全性、耐受性、最大耐受剂量和初步疗效。吉西他滨每周静脉给药共6次,剂量递增至200 mg/m2,未观察到剂量限制性毒性。中位无进展生存期(PFS)为4.8个月(95%CI 4.0-5.7),中位总生存期(MOS)为8.7个月(95%CI 7.0-10.4),与文献报道无显著差异。
要点
- 吉西他滨每周一次至200 mg/m2联合同步放疗耐受良好,未观察到剂量限制性毒性。
- 全部患者肿瘤相关症状减轻,生活质量在治疗期间趋于改善。
- PFS 4.8个月、MOS 8.7个月,与文献报道无显著差异。
核心结论
- 吉西他滨每周一次至200 mg/m2联合同步放疗在新诊断DIPG儿童中安全且耐受良好。
- PFS和MOS与文献报道无显著差异。
研究设计与样本
- I/II期、开放标签、单臂试验,采用3+3剂量递增方案,不设扩展队列。
- 2012年6月至2016年12月共入组9例新诊断DIPG儿童。
- 吉西他滨每周静脉给药共6次,联合同步6周超分割放疗,剂量依次为140、175和200 mg/m2。
主要发现
- 治疗耐受良好,至最大剂量200 mg/m2未观察到剂量限制性毒性。
- 全部患者肿瘤相关症状减轻,生活质量在治疗期间趋于改善。
- PFS为4.8个月(95%CI 4.0-5.7),MOS为8.7个月(95%CI 7.0-10.4)。
- 按新开发的DIPG生存预测模型分层,中危组(n=4)PFS和MOS分别为6.4个月和12.4个月,高危组(n=5)PFS和MOS分别为4.5个月和8.1个月。
关键数值与推荐
- 剂量限制性毒性在治疗期间监测。
- 临床反应采用预设病例报告表评估,影像学反应采用改良RANO标准评估。
- 生活质量采用PedsQL问卷评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this phase I/II, open-label, single-arm trial is to investigate the safety, tolerability, maximum tolerated dose and preliminary efficacy of the potential radiosensitizer gemcitabine, administered concomitantly to radiotherapy, in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Six doses of weekly gemcitabine were administered intravenously, concomitantly to 6 weeks of hyperfractionated radiotherapy. Successive cohorts received increasing doses of 140, 175 and 200 mg/m2 gemcitabine, respectively, following a 3 + 3 dose-escalation schedule without expansion cohort. Dose-limiting toxicities (DLT) were monitored during treatment period. Clinical response was assessed using predefined case report forms and radiological response was assessed using the modified RANO criteria. Quality of life (QoL) was assessed using PedsQL questionnaires. Between June 2012 and December 2016, nine patients were enrolled. Treatment was well tolerated, and no DLTs were observed up to the maximum dose of 200 mg/m2. All patients experienced reduction of tumor-related symptoms. QoL tended to improve during treatment. PFS and MOS were 4.8 months (95% CI 4.0-5.7) and 8.7 months (95% CI 7.0-10.4). Classifying patients according to the recently developed DIPG survival prediction model, intermediate risk patients (n = 4), showed a PFS and MOS of 6.4 and 12.4 months, respectively, versus a PFS and MOS of 4.5 and 8.1 months, respectively, in high risk patient (n = 5). Gemcitabine up to 200 mg/m2/once weekly, added to radiotherapy, is safe and well tolerated in children with newly diagnosed DIPG. PFS and MOS were not significantly different from literature.
引用
- Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017. PMID: 28748343. doi:10.1007/s11060-017-2575-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。